The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).
 
Imane H. El Dika
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
James J. Harding
Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Lilly
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Polaris (Inst)
 
Anna D. Hrabovsky
No Relationships to Disclose
 
Richard K. G. Do
No Relationships to Disclose
 
Jinru Shia
No Relationships to Disclose
 
Joseph Germino
Employment - Bayer
Research Funding - Bayer
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); Amgen; Antengene (I); Aptus Clinical; ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Gilead Sciences; Halozyme (I); Inovio Pharmaceuticals; Ipsen (I); Merck (I); Merrimack; Onxeo (I); PCI Biotech (I); Sanofi; Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); Yakult Pharmaceutical (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Roche (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb (I); CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Gilead Sciences (I); Halozyme; Halozyme (I); Inovio Pharmaceuticals; Ipsen; Medimmune; Merck Serono; Onxeo; PCI Biotech; Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; Vicus Therapeutics (I); Yakult Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris